Casano-Sancho Paula
Pediatric Endocrinology Unit, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. ESPE Membership.
Arch Dis Child. 2017 Jun;102(6):572-577. doi: 10.1136/archdischild-2016-311609. Epub 2016 Nov 21.
In the past decade, several studies in adults and children have described the risk of pituitary dysfunction after traumatic brain injury (TBI). As a result, an international consensus statement recommended follow-up on the survivors. This paper reviews published studies regarding hypopituitarism after TBI in children and compares their results. The prevalence of hypopituitarism ranges from 5% to 57%. Growth hormone (GH) and ACTH deficiency are the most common, followed by gonadotropins and thyroid-stimulating hormone. Paediatric studies have failed to identify risk factors for developing hypopituitarism, and therefore we have no tools to restrict screening in severe TBI. In addition, the present review highlights the lack of a unified follow-up and the fact that unrecognised pituitary dysfunction is frequent in paediatric population. The effect of hormonal replacement in patient recovery is important enough to consider baseline screening and reassessment between 6 and 12 months after TBI. Medical community should be aware of the risk of pituitary dysfunction in these patients, given the high prevalence of endocrine dysfunction already reported in the studies. Longer prospective studies are needed to uncover the natural course of pituitary dysfunction, and new studies should be designed to test the benefit of hormonal replacement in metabolic, cognitive and functional outcome in these patients.
在过去十年中,针对成人和儿童的多项研究描述了创伤性脑损伤(TBI)后垂体功能障碍的风险。因此,一份国际共识声明建议对幸存者进行随访。本文回顾了已发表的关于儿童TBI后垂体功能减退的研究,并比较了它们的结果。垂体功能减退的患病率在5%至57%之间。生长激素(GH)和促肾上腺皮质激素(ACTH)缺乏最为常见,其次是促性腺激素和促甲状腺激素。儿科研究未能确定发生垂体功能减退的风险因素,因此我们没有工具来限制对重度TBI患者的筛查。此外,本综述强调了缺乏统一的随访,以及在儿科人群中未被识别的垂体功能障碍很常见这一事实。激素替代对患者康复的影响非常重要,足以考虑在TBI后6至12个月进行基线筛查和重新评估。鉴于这些研究中已报道的内分泌功能障碍的高患病率,医学界应意识到这些患者垂体功能障碍的风险。需要进行更长时间的前瞻性研究来揭示垂体功能障碍的自然病程,并且应该设计新的研究来测试激素替代对这些患者的代谢、认知和功能结局的益处。